HR Execs on the Move

RaNA Therapeutics

www.ranarx.com

 
RaNA Therapeutics is pioneering the discovery of a new class of RNA-targeted medicines that selectively activate protein expression within the body`s own cells. By targeting specific genes, RaNA`s novel drugs work epigenetically to precisely upregulate the expression of beneficial proteins in order to treat or prevent disease. The company`s leadership leverages preeminent founders and advisors in the field, and the strength of its fundamental patents, technology, and know-how that underlie the discovery and development of therapeutics that selectively activate RNA. RaNA is applying its proprietary technology to rapidly advance a pipeline of novel drugs for diverse therapeutic areas, with an initial ...
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million
  • www.ranarx.com
  • 790 Memorial Dr Ste 203
    Cambridge, MA USA 02139
  • Phone: 617.945.7361

Executives

Name Title Contact Details

Similar Companies

LifeGuard America

LifeGuard America is a Tulsa, OK-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Consortium for Conservation Medicine

Consortium for Conservation Medicine is a Palisades, NY-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Good Samaritan Lutheran Health

Good Samaritan Lutheran Health is a Delmar, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Berg LLC

BERG is a Boston-based biopharma company focused on taking a bold “back to biology” approach to therapeutic discovery using its unique AI-based Interrogative Biology® platform. This platform combines patient biology and AI-based analytics to engage the differences between healthy and disease environments. The patient’s own biology drives the platform’s results and guides us in the discovery and development of drugs, diagnostics and healthcare applications. Our platform utilizes patient population health data to bring actionable Patient IntelligenceTM to precision medicine applications. For patients this means faster discovery and development of treatments, more effective precision treatments for individuals as well as a reduction in costs to our healthcare systems. BERG has a robust product portfolio in oncology, endocrinology and neurology with mature assets in oncology entering mid and late stage trials. BERG is committed to improving the lives of patients through precision medicine made possible by our innovative platforms.